News Releases

Jasper Therapeutics to Present at Upcoming Conferences

March 9, 2023
REDWOOD CITY, Calif. , March 09, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on developing novel antibody therapies targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria and lower to intermediate risk myelodysplastic

Jasper Therapeutics Announces Positive Follow-up Clinical Data from Investigator-Sponsored Study of Briquilimab Conditioning in Fanconi Anemia Patients at the 2023 Transplantation & Cellular Therapy Meetings of the ASTCT and CIBMTR

February 17, 2023
Both Fanconi Anemia patients treated with briquilimab successfully engrafted with neutrophil engraftment within 11 days 100% total donor chimerism was achieved through six months for the first patient and through three months for the second patient Both patients are doing well post-transplant with
Displaying 11 - 20 of 31

External Link

You are now leaving the Jasper Therapeutics, Inc. site to a 3rd party website. Jasper Therapeutics is not responsible for 3rd party website content.